Gene therapy injection for ALS: safety study
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a single injection of SNUG01 into the spinal fluid to see if it is safe and could help people with ALS. It is an early study to check for side effects and how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALS (probable or definite).
- Your symptoms started within the last 3 years.
- You are between 18 and 80 years old.
- Your breathing test (FVC) is at least 70% of normal.
- Your ALS functional score is 26 or higher.
- You have not had gene therapy or an organ transplant before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This trial tests a new gene therapy called SNUG01 for adults with ALS. It aims to see if the treatment is safe and can slow the disease. You may be eligible if you are diagnosed early (within 2 years) and have good breathing function.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This trial tests a new drug called RAG-21 for people with ALS who have a specific change in their FUS gene. The goal is to see if it is safe and if it can slow down the disease.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.